+

WO1998036278A1 - Essai d'anticorps par immunocapture en plusieurs sites et necessaire correspondant - Google Patents

Essai d'anticorps par immunocapture en plusieurs sites et necessaire correspondant Download PDF

Info

Publication number
WO1998036278A1
WO1998036278A1 PCT/US1998/002723 US9802723W WO9836278A1 WO 1998036278 A1 WO1998036278 A1 WO 1998036278A1 US 9802723 W US9802723 W US 9802723W WO 9836278 A1 WO9836278 A1 WO 9836278A1
Authority
WO
WIPO (PCT)
Prior art keywords
analyte
concentration
sample
reagent
labeling
Prior art date
Application number
PCT/US1998/002723
Other languages
English (en)
Inventor
Juan G. Alvarez
Gene A. Davis
Original Assignee
Beth Israel Deaconess Medical Center, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center, Inc. filed Critical Beth Israel Deaconess Medical Center, Inc.
Priority to AU62774/98A priority Critical patent/AU6277498A/en
Publication of WO1998036278A1 publication Critical patent/WO1998036278A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors

Definitions

  • radioimmunoassay A variety of immunoassay procedures have been developed to determine the presence and/or concentration of biologically active substances in a sample. For example, in a radioimmunoassay, a sample containing an unknown concentration of antigen is mixed with a fixed amount of antibody and a fixed amount of antigen, which has been radioactively labeled. The resultant antibody/antigen complex is recovered and its radioactivity measured to determine the relative concentrations of the radioactive antigen and the antigen contributed by the sample to determine the concentration of the antigen in the sample.
  • radioimmunoassays suffer from certain disadvantages, including cost, handling, storage and disposal of radioisotopes, and are in general performed by trained personnel.
  • Enzyme immunoassays employ an enzyme labeled antibody conjugate directed against the antigen which is being detected and measured, and a primary antibody directed against the antigen. After appropriate incubation and separation procedures, detection of the enzyme (e.g. based on enzymatic production of color or fluorescence) provides for detection of the antigen. The resulting color intensity or fluorescence may be visually compared to a color guide for a qualitative or semi- qualitative determination. Alternatively, the resulting color intensity or fluorescence may be measured through electronic means, e.g. by density or reflectance photometry for a quantitative determination. To facilitate the separation of bound from unbound reactants, most EIA techniques are enzyme-linked immunosorbent assays (ELISA). Common to ELISA techniques is the binding or attachment of the primary antibody to a solid or impermeable support.
  • ELISA enzyme-linked immunosorbent assays
  • RIAs and EIAs can be performed in a competitive or non-competitive format.
  • competitive immunoassays are performed by adding an appropriate volume of labeled analyte and analyte-specific reagent to a sample containing the analyte, so that the labeled analyte and the analyte in the sample compete for a limited number of analyte-specific reagent binding sites, resulting in the formation of sample analyte/reagent and labeled-analyte/ reagent complexes.
  • the amount of labeled-analyte/reagent complex formed is inversely proportional to the amount of analyte present in the sample.
  • a quantitative determination of the analyte can therefore be made based on the labeled analyte/reagent complex.
  • Competitive assays can be homogeneous (i.e. not requiring separation of antibody bound tracer (e.g. labeled analyte) from free tracer, since the antigen-antibody interaction causes, directly or indirectly, a measurable change in the signal obtained from the label group of the analyte).
  • competitive assays can be heterogeneous (i.e. requiring separation of bound analyte from free analyte prior to determining the amount of analyte in the sample).
  • non-competitive assays involve incubating an analyte containing sample with an immobilized analyte-specific (capture) reagent for a period of time sufficient to reach equilibrium with regard to the formation of reagent/analyte conjugates.
  • the analyte-specific reagent can be directly or indirectly labeled.
  • indirect labeling can be carried out after a wash step to remove unbound analyte by contacting the immobilized capture reagent/analyte complexes with a second, labeled reagent that is specific for the capture reagent/analyte complex.
  • the amount of bound second labeled reagent can be detected and measured as an indication of bound analyte.
  • Agglutination immunoassays are also used to detect the presence of an analyte in a sample.
  • An agglutination reaction involves the in vitro aggregation of microscopic carrier particles as a result of the specific reaction between antibodies and antigens, one of which is immobilized on the surface of carrier particles.
  • Agglutination immunoassays can be performed in either a direct or indirect format.
  • a direct agglutination immunoassay a sample which may contain an analyte of interest (e.g. antigen or antibody) is contacted with a corresponding analyte-specific reagent (e.g. an antibody or antigen, respectively, attached to the surface of a carrier particle).
  • analyte of interest e.g. antigen or antibody
  • analyte-specific reagent e.g. an antibody or antigen, respectively, attached to the surface of a carrier particle.
  • the presence of the analyte in the sample can be directly detected based on agglutination (e.g. antibody/antigen).
  • the presence of the analyte of interest in the sample inhibits the formation of complexes.
  • the agglutination test is typically performed on a slide and read visually. As a result, it is highly subjective and requires substantial expertise. This is particularly problematic when quantitation of the antigen is important.
  • the invention features novel assay devices, which are useful for determining the concentration of an analyte in a sample.
  • the device includes a substrate including at least two detection zones, each of the detection zones comprising a pre-defined amount of an immobilized analyte-specific capture reagent.
  • a first detection zone includes a first concentration of the immobilized capture reagent
  • a second detection zone includes a second concentration of the immobilized capture reagent, the first concentration being greater than the second concentration.
  • the invention features novel assay methods for determining the concentration of an analyte in a sample.
  • the method includes the step of supplying the sample fluid to an assay device which includes a substrate.
  • the substrate includes at least two analyte detection zones.
  • Each of the analyte detection zones includes a pre-defined amount of an analyte-specific capture reagent.
  • the method includes the further step of allowing the sample fluid to contact the at least two analyte detection zones, such that the concentration of the analyte in the sample fluid is determined.
  • the invention provides a device for determining a concentration of an analyte in a sample fluid.
  • the device includes a fluid-permeable substrate having a sample application area in fluid communication with a plurality of detection zones.
  • Each of the detection zones includes a capture reagent capable of binding to the analyte, and the concentration of the capture reagent in each of the zones is different, such that the zones bind differentially to different concentrations of an analyte:labeling reagent complex.
  • the device includes a labeling area disposed on the substrate between and in fluid communication with the sample application area and the detection zones.
  • the labeling area includes (e.g., is impregnated with) a labeling reagent which is capable of binding to the analyte to form an analyte:labeling reagent complex.
  • the device is configured to allow flow of the sample fluid from the sample application area through the labeling area, such that the analyte binds to the labeling reagent to form an analyte:labeling reagent complex.
  • the device is configured to permit further flow of the analyte:labeling reagent complex to the plurality of detection zones, where the analyte and/or the complex is bound by the capture reagent, such that presence of bound label in the detection zones is indicative of concentration of the analyte in the sample.
  • the invention features novel kits, which are useful for performing the instant claimed assays.
  • Other objects, features and advantages of the invention will be apparent from the following Detailed Description and Claims.
  • FIG. 1 is a schematic depiction of a preferred embodiment of the invention. Detailed Description of the Invention
  • an analyte shall refer to a substance (e.g., a molecule or complex) that is to be detected.
  • an analyte can be any substance capable of detection in an assay method or device, and is preferably a member of a specific binding pair, e.g., one member of a pair such as antigen antibody, hormone/receptor, enzyme/substrate, nucleic acid/complementary nucleic acid, substrate/binding protein, and the like.
  • An analyte can be a compound of interest or can be indicative of a compound of interest, and may be directly or indirectly indicative of a condition, e.g., of a physiological condition such as pregnancy. It will be understood that an analyte can be either member of a specific binding pair, i.e., an analyte can be an antigen (which can be detected by way of an antibody which binds the antigen); or the analyte can be an antibody (which can be detected by use of an antigen to which it binds). In preferred embodiments, an analyte includes one or more sites at which another molecule or complex can bind or associate to form a complex (or a higher-order complex).
  • An analyte can be monovalent (i.e. contain one binding site or epitope) or polyvalent (i.e. contain more than one binding site or epitope).
  • Preferred analytes which can be detected with the devices, kits, and methods of the present invention include proteins (e.g. antibodies (e.g., antibodies against disease organisms, e.g., the causative organisms of AIDS, rubella, hepatitis, Lyme disease, and the like), hormones (such as luteinizing hormone, chorionic gonadotropin, or a steroidal hormone, such as progesterone or glucoronide), surfactant apoproteins (e.g.
  • antigens for analysis according to the methods of the invention include: hormones, therapeutic drugs (e.g. theophylline), drugs of abuse (e.g. cocaine, heroin, morphine, amphetamine, PCP, THC, barbiturate and benzodiazepine), infectious agents or other food or water contaminants (e.g. bacteria, fungi, viruses, protists) and sperm antigens.
  • therapeutic drugs e.g. theophylline
  • drugs of abuse e.g. cocaine, heroin, morphine, amphetamine, PCP, THC, barbiturate and benzodiazepine
  • infectious agents or other food or water contaminants e.g. bacteria, fungi, viruses, protists
  • sperm antigens include sperm proteins (e.g. sperm flagellar proteins, glycolytic enzymes, antioxidant enzymes (e.g.
  • sperm lipids e.g. cholesterol, phospholipids, glycolipids, triglycerides, phosphatidylglycerols, seminolipids, and fatty acids, particularly docosahexaenoic acid, which is one of the few fatty acids found in sperm
  • nucleic acids or a mixture of sperm components e.g.
  • analyte-specific reagent refers to a molecule or complex that: i) can specifically associate with or bind to an analyte to form a complex; and/or ii) can be detected or quantitated as an indication of the presence and/or quantity (e.g. concentration) of the analyte.
  • analyte-specific reagents for use in the instant invention include: antibodies (e.g. monoclonal or polyclonal) or fragments thereof (e.g.
  • analyte-specific reagents are directly or indirectly labeled (i.e. can produce a detectable signal).
  • a labeled analyte-specific reagent that can bind to an analyte and thereby label it is referred to herein as a "labeling reagent".
  • a label is a moiety that can be detected, directly or indirectly, as an indication of the presence or absence of the labeled reagent.
  • Preferred labels include enzymes (e.g., horseradish peroxidase, alkaline phosphatase, urease, ⁇ -galactosidase), enzyme co-factors, radioisotopes (e.g. -1H, ⁇ C, ⁇ , ⁇ 2p j 131j an( j 35s) ; fluorescent compounds (e.g. fluorescein, rhodamine, allophycocyanin, phycoerythin, erythrosin, europium, luminol, luciferin and coumarin), dyes, and colored or uncolored beads or particles (e.g.
  • enzymes e.g., horseradish peroxidase, alkaline phosphatase, urease, ⁇ -galactosidase
  • enzyme co-factors e.g. -1H, ⁇ C, ⁇ , ⁇ 2p j 131j an( j 35s)
  • radioisotopes
  • Preferred particles are in the range of about 0.01 to about 5 microns.
  • Many detectable labels are known in the art for use in assay methods, and selection of an appropriate label will be routine to the skilled artisan based on such factors as, e.g., ease of use or detection of the label, the chemical or physical nature of the analyte and/or the analyte-specific reagent, the cost of the label, and the like.
  • a labeling reagent will generally be soluble, or will be of a size small enough to permit the labeling reagent, bound to the analyte, to pass through the substrate, urged by fluid flow, to the plurality of detection zones.
  • capture reagent refers to an analyte-specific reagent which can be immobilized on the substrate and is capable of specific binding to the analyte, or to an analyte-specific reagent, or to a complex of an analyte with an analyte-specific reagent.
  • the capture reagent is an immobilized antibody, or fragment of an antibody.
  • detection site refers to a location or zone of the substrate which contains or is impregnated with an immobilized capture reagent, preferably in a predetermined quantity.
  • a site can have any shape or dimension consistent with detection of the analyte and readout, in combination with at least one other detection site, of an analyte concentration (quantitative or qualitative).
  • a plurality of capture sites can be configured to form any desired pattern, which can be selected, e.g., to form recognizable visible indicia upon completion of the test.
  • sample shall refer to a sample, such as a fluid, which contains or may contain the analyte to be detected.
  • the sample is a biological sample, i.e., any material obtained from a living source (e.g. human, animal, plant, bacteria, fungi, protist, virus).
  • the biological sample can be in any form, including solid materials (e.g., tissue, cell pellets and biopsies) and biological fluids (e.g. urine, blood, saliva, amniotic fluid and a mouth wash (e.g., containing buccal cells)).
  • a solid material is suspended or dissolved in a liquid prior to analysis according to the invention.
  • Substrate refers to an insoluble substance (or a plurality of insoluble components), usually at least partially porous and fluid-permeable, which generally (in preferred embodiments) includes a sample application area (i.e. an area for receiving the applied sample) in fluid communication with an analyte-specific reagent area (i.e., an area which contains or is impregnated with an analyte-specific reagent such as a labeling reagent), which further includes a plurality of detection sites (e.g. 2, 3, 4, 5, 6, 7, 8 or more) each containing an immobilized capture reagent.
  • Preferred substrates for use in the invention include membranes or filters (e.g.
  • a substrate can comprise a plurality of parts, which can be composed of the same material or of different materials, if desired, provided that the parts are in fluid communication, and permit the sample fluid to be communicated from a sample application area to a plurality of detection sites.
  • a substrate can include wicking elements, filter elements (e.g., for filtering out solid particles), reservoir elements (e.g., for holding a supplying a sample fluid), and the like.
  • a substrate can be configured for sample application either to a discrete sample application area, or, in certain embodiments, can be configured for dipping into a sample fluid.
  • Dipstick-type assay devices are well-known in the art (see, e.g., EP-A 0 125 118 or EP-A 0 282 192).
  • the substrate can be housed in a housing, or otherwise fixed to a supporting member, which can include features such as a viewing window, a handle for easier manipulation by a user, and the like.
  • concentration refers to a concentration, density, or total amount of an analyte, analyte-specific reagent (such as a labeling reagent) or capture reagent, e.g., a concentration, density, or total amount of a capture reagent which is present in a selected detection site.
  • analyte-specific reagent such as a labeling reagent
  • capture reagent e.g., a concentration, density, or total amount of a capture reagent which is present in a selected detection site.
  • Figure 1 shows a schematic view of one embodiment of a device which can be used to perform assays in accordance with the methods of the invention.
  • the device comprises a (preferably substantially flat) substrate 1 of rectangular shape (although any appropriate shape may be employed).
  • Substrate 1 includes a sample application area 2, which is in fluid communication with the detection area 3.
  • the sample application area can include a bibulous reservoir pad, which can absorb and hold a portion of sample liquid.
  • the detection area 3 which is fluid- permeable, includes a plurality of capture sites (detection zones) of a defined width or other dimension (e.g., diameter of a spot) (preferably between about 0.2 mm and 5 mm, more preferably between 0.5 and 2 mm) and each site includes a pre-selected concentration of immobilized capture reagent.
  • the detection sites have a substantially linear shape.
  • the distance between any two detection sites is between about 0.5 mm and 10 mm, more preferably between about 1 mm and 5 mm.
  • at least two of the detection sites have immobilized capture reagent concentrations which differ from each other.
  • the concentration of immobilized capture reagent in each detection site in a particular device is an even multiple of the concentration of immobilized capture reagent in another detection site of the device (e.g., 1:1, 1:2. 1 :4, 1 :8, 1:16, 1 :32, etc.).
  • the immobilized capture reagent concentrations of each of a series of detection sites increases in a direction of sample fluid flow.
  • a device in which immobilized capture reagents sites are so arranged provides accurate results and is easily read.
  • the device of the invention can be housed within a fluid-impermeable housing, preferably constructed of a solid, relatively rigid material, such as plastic.
  • the housing will generally include an opening adjacent the sample application area, to permit a liquid sample to be applied to the sample application area (e.g., the reservoir pad).
  • a reservoir pad can extend out from the substrate, through an opening in the housing, to permit sample application to the exterior reservoir pad, followed by fluid communication to the portion of the substrate disposed within the housing.
  • the housing can also include a grip or handle portion to permit the user to firmly grasp the device.
  • the grip portion can be textured, e.g., ribbed, to permit easy handling.
  • the housing also preferably includes at least one window disposed over the detection area to permit inspection of the detection area.
  • a window can be an opening in the housing, or a transparent portion of the housing. More than one window may be present in the housing (e.g., a window over each detection site, or a separate window over a control site).
  • the sample When a liquid sample is applied to the sample application area, the sample is absorbed, e.g., by a reservoir pad. The sample is then wicked along the substrate (which can be of multi-part construction) to the detection zones, where the analyte concentration is read.
  • the amount (e.g., density or concentration) of the capture reagent present in any detection zone can be selected to provide a detectable amount of bound label when analyte is present in the sample in an amount or at a concentration equal to or greater than a pre-determined concentration.
  • the amount of capture reagent present in each of several detection zones can be selected such that each of the zones has a different (and preferably known) threshold sensitivity for detection of the analyte.
  • the detection zone will provide a detectable signal, e.g., a detectable amount of bound label, e.g., by binding an analyte:labeling reagent complex.
  • the number or pattern of detection zones which provide a detectable signal can then be determined to provide an indication of the concentration of analyte in the sample.
  • the amount of capture reagent in each detection zone is preferably selected to permit the device to measure analyte concentration over a range of values expected for a particular analyte and type of sample fluid.
  • the amount of capture reagent in a detection zone can be chosen to be sensitive to a pre-selected concentration of analyte in the sample fluid.
  • concentration of LH in plasma can vary between about 5 mlU/mL and 40 mlU/mL.
  • a device for determining the level of LH in plasma is preferably able to determine LH concentrations in the range of 5 to 40 mlU/mL or some subrange thereof.
  • each of the plurality of detection zones could have a threshold sensitivity to LH within the selected range or a subrange thereof.
  • a first detection zone can have a concentration of an immobilized anti-LH antibody sufficient to capture a visible amount of label when the LH concentration is at least 5 mIU/ml
  • a second detection zone can have a concentration of an immobilized anti-LH antibody sufficient to capture a visible amount of label when the LH concentration is at least 20 mlU/ml.
  • the appearance of a visible indication such as a colored spot or line, at the position of the first detection zone, would indicate an LH concentration of at least 5 mlU/ml.
  • the LH concentration of the sample is at least 5 mlU/ml, but less than 20 mlU/ml.
  • Different sensitivities in the plurality of reaction zones can be achieved, e.g., by providing an amount of the capture reagent in each of the detection zones sufficient to permit a detectable amount of a label to be bound to each detection zone at the threshold concentration of LH in a plasma sample.
  • the required amount of capture reagent in each zone will vary depending upon such factors as the affinity of the capture reagent for the analyte (or label) to which it binds. Such concentrations can be readily determined by one of ordinary skill in the art with no more than routine experimentation.
  • different capture reagents such as two different monoclonal antibodies which bind to a single analyte, or analyte/labeling reagent complex
  • the different capture reagents have differing affinities for the reagent.
  • a capture reagent such as an antibody
  • differing detection zones can be provided with differing sensitivities to the analyte, thereby providing differential detection of the analyte and permitting quantitation of the analyte concentration.
  • the concentration of immobilized capture reagent is lowest in the capture reagent site (detection zone) closest to the sample application area, and the concentration of immobilized capture reagent increases in successive detection zones in the direction of fluid flow (indicated in Figure 1 by an arrow) from the sample application area.
  • the concentration of capture reagent increases from 1 : 16 at the detection site closest to the sample application area, to 1 :1 at the most distant (i.e., downstream) detection sites.
  • a first analyte detection zone is said to be "upstream” of a second analyte detection zone (which is "downstream” of the first zone) if the first zone is contacted by a fluid sample before the second zone is so contacted.
  • the fluid will flow through an upstream detection zone before passing through a downstream zone.
  • the device may optionally include a labeling zone 4 (e.g., a zone impregnated with a labeling reagent such as gold-antibody conjugate) between and in fluid communication with the sample application area and the detection area (including the detection zones).
  • the labeling zone comprises a labeling reagent which can bind to the analyte.
  • the labeling reagent is a labeled antibody which can form a complex with the analyte.
  • the complex of labeling reagent and analyte (the analyte labeling reagent complex) can then move to the capture reagent sites (the detection zones) for capture and detection.
  • the labeling reagent is present in excess (i.e., in molar excess, e.g., at least 10%, 20%, 30% or 50%) excess) over the capture reagent (to ensure that there is enough labeling reagent to bind to the analyte and the capture reagent).
  • the label e.g., as the analyte:labeling reagent complex
  • the presence of bound label in a detection zone can then be detected, e.g., by means identified herein, including visual inspection.
  • the device when the device includes a labeling zone, the device is configured to allow flow of the sample fluid from the sample application area through the labeling zone (which can also be a filter zone) such that the analyte binds to the labeling reagent to form an analyte labeling reagent complex.
  • the sample is preferably filtered to remove large, potentially interfering particles as the sample flows through the (optional)filter zone.
  • the device is also configured to permit flow of the analyte:labeling reagent complex to the detection zones, where the complex is captured by the immobilized capture reagent, so that presence of bound label in the detection zones is indicative of concentration of the analyte in the sample.
  • the labeling reagent comprises a colored particle, preferably colloidal gold, and the concentration of the analyte in the sample is determined visually.
  • the capture reagent comprises an antibody, more preferably a monoclonal antibody.
  • Assay devices commonly (but optionally) include a control site, typically disposed on the substrate downstream of the capture zones.
  • the control site is not sensitive to the presence or absence of analyte in the sample, but is sensitive to the presence or absence of another component of the sample fluid, or to the labeling reagent, if present.
  • Such a control site provides an indication that the sample fluid has been correctly applied to the assay device by providing a visible indication that the fluid has flowed to the control site (and therefore to the capture sites).
  • the device may optionally include a "sink"
  • the sink is sited downstream of the sample application area and capture zones.
  • a preferred sink is described in International Patent Application No. WO 92/01226 to Unilever PLC.
  • the invention provides an immunochemical assay device for detecting the presence or absence of an analyte of interest in a liquid sample, the device comprising a bibulous reservoir pad for receiving and containing the liquid sample; (optionally) a filter zone adjacent to and in fluid communication with the reservoir pad, the filter zone including a labeled immunochemical reagent (i.e., a labeling reagent such as a labeled antibody) capable of binding to the analyte to form a complex; and a wicking membrane adjacent to and in fluid communication with the reservoir (or the filter zone, if present).
  • a labeled immunochemical reagent i.e., a labeling reagent such as a labeled antibody
  • the wicking membrane is capable of absorbing a portion of the liquid sample from the reservoir pad (and filter zone if present), and includes a plurality of detection zones, each detection zone including an immobilized capture reagent (such as an immobilized antibody) capable of binding to the complex (i.e., the analyte/immunochemical reagent complex).
  • the reservoir pad, filter zone, and wicking membrane can be constructed of the same or different materials, and can be disposed on solid support or within a housing (preferably a liquid-impermeable housing having at least one window for viewing the plurality of detection zones), as is conventional.
  • the filter zone if present is preferably capable of filtering out sample particles which could interfere with the assay, while permitting passage of the analyte and the complex from the reservoir pad to the wicking membrane.
  • the antibodies can be polyclonal or monoclonal antibodies.
  • an assay can be performed as described herein in a short period of time, e.g., in less than 20 minutes, more preferably less than 15, 10, 5, or 3 minutes.
  • the results of the assay can be read manually, e.g., by visual inspection, or automatically, e.g., by machine methods such as scanning densitometry (e.g., see Example 1, infra).
  • the analyte concentration can be determined directly, e.g., by reading the number of visualized analyte detection sites, or by comparing signal intensity (e.g., color intensity) to a control scale.
  • a control scale can be provided, e.g., as part of the instructions or packaging for an assay kit of the invention.
  • the detection sites can be configured on the substrate so as to permit automated readout, e.g., by a bar-code reader.
  • the width and separation of the detection sites can be selected to provide a bar-coded assay result which can be read by a conventional bar-code scanner; the resulting bar-code can then be compared, e.g., in a computer memory, to a stored value for determination of analyte concentration.
  • the width of the detection site will affect the sensitivity and readability of the assay, e.g., a line which is narrow may not be large enough for detection with the unaided eye, while a line which is excessively broad may provide an ambiguous result.
  • the concentration of immobilized capture reagent to be employed in each of the detection zones will be determined, at least in part, by considerations such as the concentration of the analyte expected to be present in sample (e.g., as described below, levels of luteinizing hormone in plasma commonly are in the range of from about 5 mlU/mL to about 40 mlU/mL), the nature and sensitivity of the reagent used to detect or visualize the presence of analyte (e.g., colorimetric assay or presence of colored particles), the expense of the capture reagent, and the like.
  • concentration of the analyte expected to be present in sample e.g., as described below, levels of luteinizing hormone in plasma commonly are in the range of from about 5 mlU/mL to about 40 mlU/mL
  • the nature and sensitivity of the reagent used to detect or visualize the presence of analyte e.g., colorimetric assay or presence of colored particles
  • kits useful for assays e.g., diagnostic assays as described herein.
  • the kits include a device of the invention, together with instructions for using the device to perform an assay, e.g., to detect the presence or absence of an analyte in a sample.
  • the kits can optionally include a standard chart against which the results of the assay can be compared, e.g., to determine the concentration of the analyte in the sample.
  • immunoassays which can be used in conjunction with the novel devices of the invention include: fluorescence polarization immunoassay (FPIA), fluorescence immunoassay (FIA) and nephelometric inhibition immunoassay (NIA).
  • FPIA fluorescence polarization immunoassay
  • FIA fluorescence immunoassay
  • NIA nephelometric inhibition immunoassay
  • an appropriate amount of a sample containing the analyte is deposited onto the sample application area, so that the sample migrates to the labeling zone, where it binds to a labeling reagent (e.g., an analyte-specific antibody linked to gold colloid or colored particles).
  • a labeling reagent e.g., an analyte-specific antibody linked to gold colloid or colored particles.
  • the labeled antibody binds to the analyte to form a complex.
  • the complex e.g., a colored analyte-antibody complex
  • a portion of the analyte-antibody complex binds to the immobilized capture reagent, producing a pattern of colored bands which is characteristic and/or diagnostic for analyte concentration (at least qualitatively, and more preferably at least semi-quantitatively).
  • the pattern of colored bands can be compared to a reference chart provided with the device, to assist the user in determining the concentration of the analyte in the sample.
  • a sample containing the analyte e.g., an antigen
  • an antigen e.g., an antigen
  • This colored particle-antigen complex along with the antigen in the test specimen migrates through several capture sites at which both analyte in the sample and colored particle-antigen complex compete for binding to the capture reagent (e.g., an immobilized antibody). This in turn will produce a pattern of colored bands which is characteristic and diagnostic of antigen concentration.
  • the capture reagent e.g., an immobilized antibody
  • the devices and kits of the invention are simple and inexpensive to produce, and can be used by non-skilled individuals with a minimum of training.
  • the devices of the invention can be used by consumers or by professionals such as doctors.
  • the devices and methods of the invention can be used in the following non-limiting assays:
  • Ovulation is physiologically induced by an acute release or surge of LH by the hypophysis. This surge in LH triggers the release of an oocyte from a mature follicle in the ovary. Therefore, determination of the level of LH in plasma could be utilized to predict ovulation, which in turn permits timed intercourse to maximize the chances of achieving a pregnancy.
  • LH levels in plasma generally increase from about 5 miU/mL to about 40 mlU/mL about 24 hours prior to the occurrence of ovulation.
  • the invention described herein enables the user to assess the concentration of LH present before, during and after the LH surge. This is accomplished by the visualization of an increasing number of colored bands as the concentration of LH increases.
  • an assay device is provided according to the invention such that when the concentration of LH in urine is about 5 mlU/mL (baseline levels) no bands will be observed; if the concentration is 10 mlU/mL, one band will be observed; if the concentration is 20 miU/mL, two bands will be observed; and if the concentration is 40 mlU/mL, four bands will be observed.
  • Such a device can be prepared by impregnating bands of substrate (each band having an area in the range of about 1 mm 2 to about 10mm 2 ) with anti- ⁇ -subunit hCG antibody (capture reagent) in amounts from about 0.8 ⁇ g to about 52 ⁇ g.
  • anti- ⁇ -subunit hCG antibody include: band 1, 0.8 to 3.2 ⁇ g; band 2, 1.6 to 6.4 ⁇ g; band 3, 6.6. to 26 ⁇ g; and band 4, 13 to 52 ⁇ g.
  • a detectable label is provided by a labeling reagent such as an antibody-gold conjugate (gold-anti- ⁇ -subunit hCG antibody) impregnated in the substrate or in a filter pad contacting the substrate (the labeling zone), as described for the device of Example 1, below.
  • a labeling reagent such as an antibody-gold conjugate (gold-anti- ⁇ -subunit hCG antibody) impregnated in the substrate or in a filter pad contacting the substrate (the labeling zone), as described for the device of Example 1, below.
  • the band pattern provided by the inventive device permits a more quantitative assessment of the concentration of LH in urine than by inspection of a single band in a conventional kit format.
  • Determination of the concentration of human chorionic gonadotropic hormone (hCG) in plasma or urine is commonly used to assess the occurrence of a normal pregnancy or diagnose an ectopic pregnancy.
  • Monitoring the concentration of hCG is particularly useful in the diagnosis of an ectopic pregnancy when the concentration of hCG is ⁇ 2,000 mlU/mL, since at this stage in embryo development, the pregnancy sac is too small to be seen by ultrasound.
  • Currently available home diagnostic test kits used for the determination of hCG in urine are designed to provide a single-band endpoint as an indicator of high or low concentrations of hCG in urine.
  • the difference in color intensity of the bands produced at different hCG concentrations is often difficult to discern by the naked eye.
  • the invention described herein permits the user to better assess the concentration of hCG in urine. This is accomplished by the visualization of an increasing number of colored bands as the concentration of hCG in urine increases.
  • a typical example of the band pattern obtained using the multiband kit at different concentrations of hCG, is shown in Table 1 : when the concentration of hCG in urine is about ⁇ 50 mlU/mL, no bands are observed; if the concentration is about 250 mlU/mL, one strong and one very weak band are observed; if the concentration is about 500 mlU/mL, two strong and one weak band are observed; if the concentration is 1,000 mlU/mL, three strong and one moderate intensity band are observed; if the concentration is 2,500 mlU/mL, four strong bands are observed; and if the concentration is 5,000 mlU/mL, five strong bands are observed. Therefore, a more quantitative assessment of the concentration of hCG in urine can be obtained by viewing the pattern of the number and strength of colored bands.
  • apoproteins are obligate components of mature fetal lung surfactant.
  • Four different apoproteins have been identified in mature fetal lung surfactant isolated from amniotic fluid: A, B, C and D. These apoproteins have been shown to play a key role in the in vivo adso ⁇ tion of monolayers of dipalmitoyl phosphatidylcholine (DPPC) onto the air-liquid interface of the alveoli.
  • DPPC dipalmitoyl phosphatidylcholine
  • testing for surfactant apoproteins in amniotic fluid can be useful for predicting the occurrence of respiratory distress syndrome in pregnancies at risk for preterm delivery. For example, concentration of 1.7 ⁇ g/mL of apoprotein A in amniotic fluid is diagnostic of respiratory distress syndrome.
  • Sperm antigens can be analyzed, for example, to (i) obtain the total count of sperm in a sperm-containing sample (e.g., semen); or (ii) evaluate sperm properties related to the corresponding antigen (e.g., acrosin is a sperm acrosome-specific enzyme that plays a key role in the induction of the acrosome reaction in mammalian sperm; low acrosin levels in sperm may be associated with male infertility).
  • acrosin is a sperm acrosome-specific enzyme that plays a key role in the induction of the acrosome reaction in mammalian sperm; low acrosin levels in sperm may be associated with male infertility.
  • acrosin is a sperm acrosome-specific enzyme that plays a key role in the induction of the acrosome reaction in mammalian sperm; low acrosin levels in sper
  • sperm antigen for use in an assisted reproductive technology or as an indication of an ineffective male contraception (vasectomy) and sub-fertile samples (e.g. as an indication of a potentially infertile male donor or an effective male contraception), based on quantitation of a sperm antigen.
  • Example 1 Assay For Determining Human Chorionic Gonatotropin (hCG) Concentration in a Sample
  • the strips were then allowed to dry at room temperature for about 15 minutes, dipped in a 0.5% solution of powdered milk in phosphate-buffered saline for about 5 minutes and then dried at room temperature for about 15 minutes.
  • the proximal end of the nitrocellulose strip (the sample application area or origin) was then placed under a 0.5 x 0.5 cm filter pad embedded with colloidal gold/anti- ⁇ -hCG monoclonal antibody complex (labeling reagent) (O.E.M. Concepts Inc., Toms River, NJ).
  • the pad was impregnated with colloidal gold/anti- ⁇ -hCG monoclonal antibody complex at a ⁇ concentration of 8.62 ⁇ g/ ⁇ L.
  • a macroporous filter was placed on top of the filter pad, and then a test solution of 150 ⁇ L of hCG (Sigma Chemical Co, St. Louis, MO) at a selected concentration was placed on the filter.
  • hCG Sigma Chemical Co, St. Louis, MO
  • the flow of colloidal gold/anti- ⁇ -hCG antibody complex through the nitrocellulose strip was complete after about 3 minutes.
  • the nitrocellulose strip was then rinsed with distilled water, dried at room temperature for about 15 minutes, and the resulting bands scanned at 500 ran in the reflectance mode using a Shimadzu CS-9000 spectrodensitometer
  • Values correspond to the integration areas obtained following densitometric scanning at 500 ran of the bands generated on nitrocellulose strips.
  • concentrations of capture antibody that correspond to the different dilutions are:
  • the intensity of bands for a given analyte concentration generally increases as the concentration of immobilized capture reagent increases (without wishing to be bound by any theory, the drop-off in intensity at the second, downstream, high-concentration (1:1) detection band is believed to be due to exhaustion of the analyte, which has been captured by the other, "upstream” bands).
  • the bands having low concentration of immobilized capture reagent are not sensitive to low concentrations of analyte.
  • the analyte detection sites having low capture reagent concentration provide little or no signal, while bands having higher concentrations of capture reagent show a detectable signal.
  • the concentration of the analyte can be determined, at least approximately, by noting which of the bands provides a detectable signal, and (optionally) comparing the pattern seen with a standard or control pattern.
  • a second test strip was made as described above, except that each of the five analyte detection zones (bands) had the same concentration of capture reagent (the 1 : 1 concentration of capture antibody described above) applied. Two analyte concentrations were tested; the samples contained hCG at 1000 and 5000 mlU/mL, respectively. When a sample was applied to the test strip, and the developed strip analyzed as described above, the resulting band pattern showed substantially constant band intensity at a given analyte concentration, as would be expected.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

La présente invention concerne des dispositifs, des essais et des nécessaires d'analyse quantitative de la concentration d'un analysat dans un échantillon. Les dispositifs de l'invention comportent une pluralité de zones de détection permettant la détection et la numération de l'analysat.
PCT/US1998/002723 1997-02-15 1998-02-13 Essai d'anticorps par immunocapture en plusieurs sites et necessaire correspondant WO1998036278A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU62774/98A AU6277498A (en) 1997-02-15 1998-02-13 Multiple-site antibody capture immunoassays and kits

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3803097P 1997-02-15 1997-02-15
US60/038,030 1997-02-15

Publications (1)

Publication Number Publication Date
WO1998036278A1 true WO1998036278A1 (fr) 1998-08-20

Family

ID=21897712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/002723 WO1998036278A1 (fr) 1997-02-15 1998-02-13 Essai d'anticorps par immunocapture en plusieurs sites et necessaire correspondant

Country Status (2)

Country Link
AU (1) AU6277498A (fr)
WO (1) WO1998036278A1 (fr)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060402A1 (fr) * 1998-04-30 1999-11-25 Pharmacia & Upjohn Diagnostics Ab Dosage et kit de liaison par ligands, avec une zone de separation pour des analytes perturbateurs
WO2000042434A1 (fr) * 1999-01-09 2000-07-20 Bernd Pevec Procede et dispositif pour determiner un analyte
WO2002033413A1 (fr) * 2000-10-14 2002-04-25 Helen Lee Analyse sur bandelette reactive
WO2002044729A1 (fr) * 2000-11-30 2002-06-06 Helen Lee Systeme d'amplification de signal a entites marquees multiples
WO2002050544A1 (fr) * 2000-12-21 2002-06-27 Helen Lee Test à plusieurs cibles pour examen sanguin avant prélèvement
EP1307134A1 (fr) * 2000-08-12 2003-05-07 Humasis Co.,Ltd. Dispositif de diagnostic permettant de faire la distinction entre une grossesse normale et une grossesse extra-uterine, et procede de preparation de ce dispositif
US20040053256A1 (en) * 2000-07-07 2004-03-18 Helen Lee Detection signal and capture in dipstick assays
US6764825B1 (en) * 2000-10-13 2004-07-20 Tang J. Wang Methods and device for detecting prostate specific antigen (PSA)
US7517699B2 (en) 2000-04-14 2009-04-14 Quantrx Biomedical Corporation Positive detection lateral-flow apparatus and method for small and large analytes
WO2011119484A1 (fr) 2010-03-23 2011-09-29 Iogenetics, Llc Procédés bioinformatiques pour déterminer la liaison de peptides
WO2011150186A1 (fr) 2010-05-26 2011-12-01 The Board Of Trustees Of The University Of Illinois Glucomètres personnels de détection et quantification de large gamme de substances à analyser
US8168396B2 (en) 2009-05-11 2012-05-01 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes using differential protein glycosylation
WO2013040142A2 (fr) 2011-09-16 2013-03-21 Iogenetics, Llc Procédés bio-informatiques de détermination de liaisons peptidiques
AT512119A1 (de) * 2011-10-24 2013-05-15 Scheuringer Kim Testvorrichtung
US8476008B2 (en) 2008-07-23 2013-07-02 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes
EP2388588B1 (fr) * 2010-05-18 2013-10-30 Justus-Liebig-Universität Gießen Procédé et test rapide destinés à la détermination de la fertilité de spermatozoïdes
WO2014087255A2 (fr) 2012-11-21 2014-06-12 Oslo Universitetssykehus Hf Systèmes et procédés pour la surveillance de fluides biologiques
JP2014528067A (ja) * 2011-09-08 2014-10-23 ネクサス・ディーエックス・インコーポレイテッドＮｅｘｕｓ Ｄｘ， Ｉｎｃ． マルチレベル分析物アッセイ
WO2015023661A3 (fr) * 2013-08-12 2015-10-29 Health Research, Inc. Biomarqueurs destinés au cancer de la prostate
CN105738635A (zh) * 2015-08-21 2016-07-06 蓝十字生物药业（北京）有限公司 一种分级快速半定量测试早早孕胶体金试纸、试剂盒及检测方法
WO2016172660A1 (fr) 2015-04-23 2016-10-27 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Détection fongique à l'aide d'épitope de mannane
WO2017023929A1 (fr) 2015-08-04 2017-02-09 Cd Diagnostics, Inc. Procédés de détection d'une nécrose liée à une réaction locale indésirable sur les tissus (altr)
WO2017077392A1 (fr) 2015-11-06 2017-05-11 Oslo Universitetssykehus Hf Procédés et dispositifs permettant de détecter l'empoisonnement par le méthanol à l'aide de formiate oxydase
WO2017100454A1 (fr) 2015-12-09 2017-06-15 Intuitive Biosciences, Inc. Système automatisé d'amélioration d'argent
WO2017147186A1 (fr) 2016-02-22 2017-08-31 Ursure, Inc. Système et méthode de détection d'agents thérapeutiques pour surveiller l'adhésion à un schéma thérapeutique
WO2017178554A1 (fr) 2016-04-13 2017-10-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et trousses pour la détection rapide du clone o25b-st131 d'escherichia coli
WO2017218232A1 (fr) * 2016-06-17 2017-12-21 Siemens Healthcare Diagnostics Inc. Dispositifs, procédés et trousses pour le multiplexage d'un échantillon de fluide par réutilisation d'échantillon de fluide
WO2018203145A1 (fr) 2017-05-03 2018-11-08 Oslo Universitetssykehus Hf Systèmes et procédés pour surveiller des liquides biologiques
EP3415919A1 (fr) 2012-02-07 2018-12-19 Intuitive Biosciences Inc. Peptides spécifiques de mycobacterium tuberculosis pour la détection d'une infection ou d'une immunisation chez des primates non humains
EP3418397A1 (fr) 2012-01-24 2018-12-26 CD Diagnostics, Inc. Système de détection d'une infection dans le liquide synovial
EP3434694A1 (fr) 2010-04-09 2019-01-30 Critical Care Diagnostics, Inc. Anticorps st-2 humains solubles et dosages
CN111521769A (zh) * 2019-02-01 2020-08-11 湖南达道生物工程有限公司 一种生物样本检测方法及装置
WO2022039604A1 (fr) * 2020-08-21 2022-02-24 Pictor Limited Dosage multiplex pour la maladie de johne et la grossesse
US11300576B2 (en) 2019-01-29 2022-04-12 Arizona Board Of Regents On Behalf Of Arizona State University DARPin reagents that distinguish Alzheimer's disease and Parkinson's disease samples
CN114814243A (zh) * 2022-06-22 2022-07-29 北京芯迈微生物技术有限公司 应用于蛋白质抗原的定量检测试剂盒及方法
US11630106B2 (en) 2017-05-19 2023-04-18 Philip Morris Products S.A. Diagnostic test for distinguishing the smoking status of a subject
EP4058810A4 (fr) * 2019-11-15 2023-12-20 President And Fellows Of Harvard College Dispositif et procédé de détection d'analytes

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296724A2 (fr) * 1987-06-01 1988-12-28 Quidel Essai et dispositif utilisant une membrane non-buvant permettant un courant latéral
US4956275A (en) * 1987-04-14 1990-09-11 Molecular Devices Corporation Migratory detection immunoassay
EP0439917A1 (fr) * 1989-12-01 1991-08-07 Sangstat Medical Corporation Appareil pour la détection et la mesure semiquantitative de composés
US5073484A (en) * 1982-03-09 1991-12-17 Bio-Metric Systems, Inc. Quantitative analysis apparatus and method
EP0465266A1 (fr) * 1990-07-06 1992-01-08 Sangstat Medical Corporation Immunoessai avec un signal visuel complémentaire
US5229073A (en) * 1992-02-27 1993-07-20 Abbott Laboratories One-step competitive immunoassay for the semiquantitative determination of plasma lipoprotein(a)
WO1995013542A1 (fr) * 1993-11-12 1995-05-18 Unipath Limited Dispositifs de dosage et fabrication de ces derniers
EP0696735A1 (fr) * 1994-08-08 1996-02-14 Quidel Corporation Essai immunochromatographique à sensibilité contrÔlée
EP0702233A1 (fr) * 1993-06-02 1996-03-20 Teikoku Hormone Mfg. Co., Ltd. Procede et appareil de dosage semi-quantitatif immunochimique simple
WO1996034287A1 (fr) * 1995-04-28 1996-10-31 Quidel Corporation Dosages et dispositifs permettant de determiner si une grossesse est normale ou anormale
WO1997009620A1 (fr) * 1995-09-07 1997-03-13 Agen Biomedical Limited Procede et appareil destines a l'evaluation quantitative et semi-quantitative d'une substance a analyser
WO1997012242A1 (fr) * 1995-09-27 1997-04-03 Mercury Diagnostics Inc. Bande reactive chimique a lecture directe pour solutions aqueuses

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073484A (en) * 1982-03-09 1991-12-17 Bio-Metric Systems, Inc. Quantitative analysis apparatus and method
US4956275A (en) * 1987-04-14 1990-09-11 Molecular Devices Corporation Migratory detection immunoassay
EP0296724A2 (fr) * 1987-06-01 1988-12-28 Quidel Essai et dispositif utilisant une membrane non-buvant permettant un courant latéral
EP0439917A1 (fr) * 1989-12-01 1991-08-07 Sangstat Medical Corporation Appareil pour la détection et la mesure semiquantitative de composés
EP0465266A1 (fr) * 1990-07-06 1992-01-08 Sangstat Medical Corporation Immunoessai avec un signal visuel complémentaire
US5229073A (en) * 1992-02-27 1993-07-20 Abbott Laboratories One-step competitive immunoassay for the semiquantitative determination of plasma lipoprotein(a)
EP0702233A1 (fr) * 1993-06-02 1996-03-20 Teikoku Hormone Mfg. Co., Ltd. Procede et appareil de dosage semi-quantitatif immunochimique simple
WO1995013542A1 (fr) * 1993-11-12 1995-05-18 Unipath Limited Dispositifs de dosage et fabrication de ces derniers
EP0696735A1 (fr) * 1994-08-08 1996-02-14 Quidel Corporation Essai immunochromatographique à sensibilité contrÔlée
WO1996034287A1 (fr) * 1995-04-28 1996-10-31 Quidel Corporation Dosages et dispositifs permettant de determiner si une grossesse est normale ou anormale
WO1997009620A1 (fr) * 1995-09-07 1997-03-13 Agen Biomedical Limited Procede et appareil destines a l'evaluation quantitative et semi-quantitative d'une substance a analyser
WO1997012242A1 (fr) * 1995-09-27 1997-04-03 Mercury Diagnostics Inc. Bande reactive chimique a lecture directe pour solutions aqueuses

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737278B1 (en) 1998-04-30 2004-05-18 Pharmacia & Upjohn Diagnostic Ab Ligand binding assay and kit with a separation zone for disturbing analytes
WO1999060402A1 (fr) * 1998-04-30 1999-11-25 Pharmacia & Upjohn Diagnostics Ab Dosage et kit de liaison par ligands, avec une zone de separation pour des analytes perturbateurs
WO2000042434A1 (fr) * 1999-01-09 2000-07-20 Bernd Pevec Procede et dispositif pour determiner un analyte
US7517699B2 (en) 2000-04-14 2009-04-14 Quantrx Biomedical Corporation Positive detection lateral-flow apparatus and method for small and large analytes
US20040053256A1 (en) * 2000-07-07 2004-03-18 Helen Lee Detection signal and capture in dipstick assays
EP1307134A1 (fr) * 2000-08-12 2003-05-07 Humasis Co.,Ltd. Dispositif de diagnostic permettant de faire la distinction entre une grossesse normale et une grossesse extra-uterine, et procede de preparation de ce dispositif
EP1307134A4 (fr) * 2000-08-12 2007-01-17 Humasis Co Ltd Dispositif de diagnostic permettant de faire la distinction entre une grossesse normale et une grossesse extra-uterine, et procede de preparation de ce dispositif
US6764825B1 (en) * 2000-10-13 2004-07-20 Tang J. Wang Methods and device for detecting prostate specific antigen (PSA)
US7300761B2 (en) 2000-10-13 2007-11-27 Wang Tang J Methods and device for detecting prostate specific antigen (PSA)
WO2002033414A1 (fr) * 2000-10-14 2002-04-25 Helen Lee Detection de cibles multiples
WO2002033413A1 (fr) * 2000-10-14 2002-04-25 Helen Lee Analyse sur bandelette reactive
US7713746B2 (en) 2000-10-14 2010-05-11 Diagnostics For The Real World, Ltd. Dipstick assay
EP1710583A2 (fr) * 2000-10-14 2006-10-11 Diagnostics for the Real World, Ltd Système de jauge confirmatoire
EP1710583A3 (fr) * 2000-10-14 2006-10-18 Diagnostics for the Real World, Ltd Système de jauge confirmatoire
US7972837B2 (en) 2000-11-30 2011-07-05 Diagnostics For The Real World, Ltd. Signal enhancement system with multiple labeled-moieties
US7776617B2 (en) 2000-11-30 2010-08-17 Diagnostics For The Real World, Ltd. Signal enhancement system with multiple labeled-moieties
WO2002044729A1 (fr) * 2000-11-30 2002-06-06 Helen Lee Systeme d'amplification de signal a entites marquees multiples
US9494584B2 (en) 2000-11-30 2016-11-15 Diagnostics For The Real World, Ltd. Signal enhancement system with multiple labeled-moieties
WO2002050544A1 (fr) * 2000-12-21 2002-06-27 Helen Lee Test à plusieurs cibles pour examen sanguin avant prélèvement
US8476008B2 (en) 2008-07-23 2013-07-02 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes
US8497076B2 (en) 2009-05-11 2013-07-30 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes using differential protein glycosylation
US8168396B2 (en) 2009-05-11 2012-05-01 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes using differential protein glycosylation
US8530175B2 (en) 2009-05-11 2013-09-10 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes using differential protein glycosylation
US8497077B2 (en) 2009-05-11 2013-07-30 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes using differential protein glycosylation
WO2011119484A1 (fr) 2010-03-23 2011-09-29 Iogenetics, Llc Procédés bioinformatiques pour déterminer la liaison de peptides
EP4012714A1 (fr) 2010-03-23 2022-06-15 Iogenetics, LLC. Procédés bioinformatiques pour déterminer la liaison de peptides
EP3848394A1 (fr) 2010-04-09 2021-07-14 Critical Care Diagnostics, Inc. Anticorps st-2 humains solubles et dosages
EP3434694A1 (fr) 2010-04-09 2019-01-30 Critical Care Diagnostics, Inc. Anticorps st-2 humains solubles et dosages
EP2388588B1 (fr) * 2010-05-18 2013-10-30 Justus-Liebig-Universität Gießen Procédé et test rapide destinés à la détermination de la fertilité de spermatozoïdes
WO2011150186A1 (fr) 2010-05-26 2011-12-01 The Board Of Trustees Of The University Of Illinois Glucomètres personnels de détection et quantification de large gamme de substances à analyser
JP2014528067A (ja) * 2011-09-08 2014-10-23 ネクサス・ディーエックス・インコーポレイテッドＮｅｘｕｓ Ｄｘ， Ｉｎｃ． マルチレベル分析物アッセイ
EP2753684A4 (fr) * 2011-09-08 2015-08-26 Nexus Dx Inc Dosage de substance à analyser à plusieurs niveaux
WO2013040142A2 (fr) 2011-09-16 2013-03-21 Iogenetics, Llc Procédés bio-informatiques de détermination de liaisons peptidiques
AT512119B1 (de) * 2011-10-24 2015-10-15 Scheuringer Kim Testvorrichtung
AT512119A1 (de) * 2011-10-24 2013-05-15 Scheuringer Kim Testvorrichtung
EP3418397A1 (fr) 2012-01-24 2018-12-26 CD Diagnostics, Inc. Système de détection d'une infection dans le liquide synovial
EP3415919A1 (fr) 2012-02-07 2018-12-19 Intuitive Biosciences Inc. Peptides spécifiques de mycobacterium tuberculosis pour la détection d'une infection ou d'une immunisation chez des primates non humains
WO2014087255A2 (fr) 2012-11-21 2014-06-12 Oslo Universitetssykehus Hf Systèmes et procédés pour la surveillance de fluides biologiques
US10393746B2 (en) 2013-08-12 2019-08-27 Health Research, Inc. Kit for immunological detection of TNF-alpha, sTNFR1 and IL-8 in prostate cancer
WO2015023661A3 (fr) * 2013-08-12 2015-10-29 Health Research, Inc. Biomarqueurs destinés au cancer de la prostate
US9995748B2 (en) 2013-08-12 2018-06-12 Health Research, Inc. Biomarkers for prostate cancer comprising interleukin-8 (IL-8), tumor necrosis factor alpha and soluble tumor necrosis factor-alpha receptor 1
WO2016172660A1 (fr) 2015-04-23 2016-10-27 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Détection fongique à l'aide d'épitope de mannane
WO2017023929A1 (fr) 2015-08-04 2017-02-09 Cd Diagnostics, Inc. Procédés de détection d'une nécrose liée à une réaction locale indésirable sur les tissus (altr)
CN105738635A (zh) * 2015-08-21 2016-07-06 蓝十字生物药业（北京）有限公司 一种分级快速半定量测试早早孕胶体金试纸、试剂盒及检测方法
WO2017077392A1 (fr) 2015-11-06 2017-05-11 Oslo Universitetssykehus Hf Procédés et dispositifs permettant de détecter l'empoisonnement par le méthanol à l'aide de formiate oxydase
WO2017100454A1 (fr) 2015-12-09 2017-06-15 Intuitive Biosciences, Inc. Système automatisé d'amélioration d'argent
EP3978619A1 (fr) 2015-12-09 2022-04-06 Intuitive Biosciences, Inc. Système automatisé d'amélioration d'argent
WO2017147186A1 (fr) 2016-02-22 2017-08-31 Ursure, Inc. Système et méthode de détection d'agents thérapeutiques pour surveiller l'adhésion à un schéma thérapeutique
WO2017178554A1 (fr) 2016-04-13 2017-10-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et trousses pour la détection rapide du clone o25b-st131 d'escherichia coli
WO2017218232A1 (fr) * 2016-06-17 2017-12-21 Siemens Healthcare Diagnostics Inc. Dispositifs, procédés et trousses pour le multiplexage d'un échantillon de fluide par réutilisation d'échantillon de fluide
US11585808B2 (en) 2016-06-17 2023-02-21 Siemens Healthcare Diagnostics Inc. Devices, methods, and kits for multiplexing a fluid sample via fluid sample reuse
WO2018203145A1 (fr) 2017-05-03 2018-11-08 Oslo Universitetssykehus Hf Systèmes et procédés pour surveiller des liquides biologiques
US11630106B2 (en) 2017-05-19 2023-04-18 Philip Morris Products S.A. Diagnostic test for distinguishing the smoking status of a subject
US11300576B2 (en) 2019-01-29 2022-04-12 Arizona Board Of Regents On Behalf Of Arizona State University DARPin reagents that distinguish Alzheimer's disease and Parkinson's disease samples
CN111521769A (zh) * 2019-02-01 2020-08-11 湖南达道生物工程有限公司 一种生物样本检测方法及装置
EP4058810A4 (fr) * 2019-11-15 2023-12-20 President And Fellows Of Harvard College Dispositif et procédé de détection d'analytes
WO2022039604A1 (fr) * 2020-08-21 2022-02-24 Pictor Limited Dosage multiplex pour la maladie de johne et la grossesse
CN114814243A (zh) * 2022-06-22 2022-07-29 北京芯迈微生物技术有限公司 应用于蛋白质抗原的定量检测试剂盒及方法
CN114814243B (zh) * 2022-06-22 2022-09-27 北京芯迈微生物技术有限公司 应用于蛋白质抗原的定量检测试剂盒及方法

Also Published As

Publication number Publication date
AU6277498A (en) 1998-09-08

Similar Documents

Publication Publication Date Title
WO1998036278A1 (fr) Essai d'anticorps par immunocapture en plusieurs sites et necessaire correspondant
EP1003037B1 (fr) Dispositif d'essai analytique et méthode pour son utilisation
AU2008221293B2 (en) Diagnostic detection device
EP0987550B1 (fr) Dispositif analytique et méthode d'utilisation
EP0250137B1 (fr) Essai immunologique utilisant de l'or colloidal
US5030555A (en) Membrane-strip reagent serodiagnostic apparatus and method
KR920009420B1 (ko) 고체상 분석장치 및 이를 이용하는 방법
EP0480497B1 (fr) Appareil pour l'exécution d'un dosage à la main unique et rapide
JP5173808B2 (ja) 横向き移動でのイムノクロマトの手段による検体アッセイ
US8999728B2 (en) Diagnostic detection device
JP7267211B2 (ja) 高濃度の分析物等、分析物を測定するための用量反応曲線の減少信号部分を使用したサンドイッチ型アッセイ
JPH02132375A (ja) 着色粒子イムノアッセイ用の試験装置および方法
JP2004511807A (ja) 体液サンプル中のｒｓウイルスに関連した生物学的細胞の直接的検出のためのアッセイ
CN104246502A (zh) 用于测定至少一种能够包含在液体样品中的分析物的装置
CN113588960A (zh) 一种比率荧光法免疫层析检测试条及其检测方法
KR20220007021A (ko) 라텍스 비드, 링커 및 항체를 포함하는 면역 크로마토그래피용 시약 및 이를 포함하는 래피드 키트
WO1992018869A1 (fr) Dispositif de reference a coloration rapide pour dosages immunologiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998535902

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载